Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2013-09-30
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion
NCT02144662
Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion
NCT02169648
Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
NCT01377597
Ranibizumab in Patients With Branch Retinal Vein Occlusion
NCT01027481
Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)
NCT00942864
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intravitreal Lucentis 0.5mg
One arm
Ranibizumab, 0.5mg, Intravitreal
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ranibizumab, 0.5mg, Intravitreal
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female of aged 18 years or older
* Macula edema secondary to BRVO/CRVO
* Decrease of VA due to macular edema
Exclusion Criteria
* Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye)
* Ocular disorders in the study eye that may confound interpretation of study results
* History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO
* The pregnant or lactating woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Kyoto University, Graduate School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nagahisa Yoshimura
Department of Ophthalmology & Visual Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Ophthalmology, Kyoto University Hospital
Kyoto, Kyoto, Japan
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY-RV-R
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.